Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT01959282




Registration number
NCT01959282
Ethics application status
Date submitted
7/10/2013
Date registered
10/10/2013
Date last updated
4/01/2019

Titles & IDs
Public title
A Study of Safety and Effectiveness of JNJ-54781532 in Patients With Moderately to Severely Active Ulcerative Colitis
Scientific title
A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose-response Study Evaluating the Efficacy and Safety of JNJ-54781532 in Subjects With Moderately to Severely Active Ulcerative Colitis
Secondary ID [1] 0 0
54781532UCO2001
Secondary ID [2] 0 0
CR102640
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Colitis, Ulcerative 0 0
Condition category
Condition code
Oral and Gastrointestinal 0 0 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders
Oral and Gastrointestinal 0 0 0 0
Inflammatory bowel disease

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Placebo
Treatment: Drugs - JNJ-54781532 25 mg once daily
Treatment: Drugs - JNJ-54781532 75 mg once daily
Treatment: Drugs - JNJ-54781532 150 mg once daily
Treatment: Drugs - JNJ-54781532 75 mg twice daily

Placebo Comparator: Placebo - Participants will receive placebo once daily from Week 0 to Week 8. Participants in clinical response at Week 8 will continue to receive placebo through Week 32. Participants not in clinical response at Week 8 will receive treatment with 150 mg JNJ-54781532 orally once daily from Week 8 to Week 16. Participants who achieve a partial Mayo score response (ie, a change from baseline of =3 in the partial Mayo score) at Week 16 can continue receiving 150 mg JNJ-54781532 orally once daily through Week 32

Experimental: JNJ-54781532 25 mg once daily - Participants will receive 25 mg of JNJ-54781532 once daily from Week 0 to Week 8. Participants in clinical response at Week 8 will continue to receive the same dosage through Week 32 and participants not in clinical response at Week 8 will continue to receive the same dosage through Week 16. At Week 16, participants who do not achieve a partial Mayo score response (ie, a change from baseline of =3 in the partial Mayo score) will be discontinued from study medication, and participants who achieve a partial Mayo score response at Week 16 can continue receiving JNJ 54781532 25 mg once daily through Week 32

Experimental: JNJ-54781532 75 mg once daily - Participants will receive 75 mg of JNJ-54781532 once daily from Week 0 to Week 8. Participants in clinical response at Week 8 will continue to receive the same dosage through Week 32 and participants not in clinical response at Week 8 will continue to receive the same dosage through Week 16. At Week 16, participants who do not achieve a partial Mayo score response (ie, a change from baseline of =3 in the partial Mayo score) will be discontinued from study medication, and participants who achieve a partial Mayo score response at Week 16 can continue receiving JNJ 54781532 75 mg once daily through Week 32

Experimental: JNJ-54781532 150 mg once daily - Participants will receive 150 mg of JNJ-54781532 once daily from Week 0 to Week 8. Participants in clinical response at Week 8 will continue to receive the same dosage through Week 32 and participants not in clinical response at Week 8 will continue to receive the same dosage through Week 16. At Week 16, participants who do not achieve a partial Mayo score response (ie, a change from baseline of =3 in the partial Mayo score) will be discontinued from study medication, and participants who achieve a partial Mayo score response at Week 16 can continue receiving JNJ 54781532 150 mg once daily through Week 32

Experimental: JNJ-54781532 75 mg twice daily - Participants will receive 75 mg of JNJ-54781532 twice daily from Week 0 to Week 8. Participants in clinical response at Week 8 will continue to receive the same dosage through Week 32 and participants not in clinical response at Week 8 will continue to receive the same dosage through Week 16. At Week 16, participants who do not achieve a partial Mayo score response (ie, a change from baseline of =3 in the partial Mayo score) will be discontinued from study medication, and participants who achieve a partial Mayo score response at Week 16 can continue receiving JNJ 54781532 75 mg twice daily through Week 32


Treatment: Drugs: Placebo
Participants will receive placebo once daily

Treatment: Drugs: JNJ-54781532 25 mg once daily
Participants will receive 25 mg of JNJ-54781532 once daily

Treatment: Drugs: JNJ-54781532 75 mg once daily
Participants will receive 75 mg of JNJ-54781532 once daily

Treatment: Drugs: JNJ-54781532 150 mg once daily
Participants will receive 150 mg of JNJ-54781532 once daily

Treatment: Drugs: JNJ-54781532 75 mg twice daily
Participants will receive 75 mg of JNJ-54781532 twice daily
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change from baseline in the Mayo score at Week 8
Timepoint [1] 0 0
Week 8
Secondary outcome [1] 0 0
Number of participants with clinical response at Week 8
Timepoint [1] 0 0
Week 8
Secondary outcome [2] 0 0
Number of participants with clinical remission at Week 8
Timepoint [2] 0 0
Week 8
Secondary outcome [3] 0 0
Number of participants with mucosal healing at Week 8
Timepoint [3] 0 0
Week 8

Eligibility
Key inclusion criteria
- Have a clinical diagnosis of ulcerative colitis (UC) at least 3 months prior to
screening

- Have moderately to severely active UC, defined as a baseline (Week 0) Mayo score of 6
to 12; including an endoscopy sub score greater than or equal to 2 as determined by a
central read of the video endoscopy

- Current treatment with oral corticosteroids or have a history of failure to respond
to, or tolerate, at least 1 of the following therapies oral corticosteroids (including
budesonide), 6-mercaptopurine (6-MP), azathioprine (AZA), or anti- tumor necrosis
factor therapy or be corticosteroid dependent (ie, an inability to successfully taper
corticosteroids without a return of the symptoms of UC)

- Must discontinue 6-MP/AZA for at least 1 week before the first dose of study
medication
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- At imminent risk for colectomy

- Have ulcerative colitis limited to the rectum only or to less than 20 centimeter of
the colon

- Presence of a stoma

- Presence or history of a fistula

- History or current diagnosis of active or latent tuberculosis; human immunodeficiency
virus; hepatitis C virus or hepatitis B virus infection; have had more than 1 herpes
zoster infection or have had any diagnosis of disseminated herpes zoster

- Previous treatment with a janus kinase inhibitor (eg, tofacitinib)

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
15/11/2013
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
5/12/2015
Sample size
Target
Accrual to date
Final
219
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
- Bankstown
Recruitment hospital [2] 0 0
- Bedford
Recruitment hospital [3] 0 0
- Concord
Recruitment hospital [4] 0 0
- Herston
Recruitment hospital [5] 0 0
- Launceston
Recruitment hospital [6] 0 0
- Melbourne
Recruitment hospital [7] 0 0
- Penrith
Recruitment hospital [8] 0 0
- South Brisbane
Recruitment postcode(s) [1] 0 0
- Bankstown
Recruitment postcode(s) [2] 0 0
- Bedford
Recruitment postcode(s) [3] 0 0
- Concord
Recruitment postcode(s) [4] 0 0
- Herston
Recruitment postcode(s) [5] 0 0
- Launceston
Recruitment postcode(s) [6] 0 0
- Melbourne
Recruitment postcode(s) [7] 0 0
- Penrith
Recruitment postcode(s) [8] 0 0
- South Brisbane
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Colorado
Country [3] 0 0
United States of America
State/province [3] 0 0
Michigan
Country [4] 0 0
United States of America
State/province [4] 0 0
Mississippi
Country [5] 0 0
United States of America
State/province [5] 0 0
New Jersey
Country [6] 0 0
United States of America
State/province [6] 0 0
North Carolina
Country [7] 0 0
United States of America
State/province [7] 0 0
Ohio
Country [8] 0 0
United States of America
State/province [8] 0 0
Oklahoma
Country [9] 0 0
United States of America
State/province [9] 0 0
Tennessee
Country [10] 0 0
United States of America
State/province [10] 0 0
Texas
Country [11] 0 0
United States of America
State/province [11] 0 0
Virginia
Country [12] 0 0
United States of America
State/province [12] 0 0
Washington
Country [13] 0 0
Belgium
State/province [13] 0 0
Brussel
Country [14] 0 0
Belgium
State/province [14] 0 0
Gent
Country [15] 0 0
Belgium
State/province [15] 0 0
Kortrijk
Country [16] 0 0
Belgium
State/province [16] 0 0
Leuven
Country [17] 0 0
Bulgaria
State/province [17] 0 0
Pleven
Country [18] 0 0
Bulgaria
State/province [18] 0 0
Sofia
Country [19] 0 0
Bulgaria
State/province [19] 0 0
Varna
Country [20] 0 0
Canada
State/province [20] 0 0
Alberta
Country [21] 0 0
Canada
State/province [21] 0 0
British Columbia
Country [22] 0 0
Canada
State/province [22] 0 0
Manitoba
Country [23] 0 0
Canada
State/province [23] 0 0
Ontario
Country [24] 0 0
Canada
State/province [24] 0 0
Quebec
Country [25] 0 0
France
State/province [25] 0 0
Lille Cedex
Country [26] 0 0
France
State/province [26] 0 0
Paris
Country [27] 0 0
France
State/province [27] 0 0
Pessac
Country [28] 0 0
Germany
State/province [28] 0 0
Berlin
Country [29] 0 0
Germany
State/province [29] 0 0
Essen
Country [30] 0 0
Germany
State/province [30] 0 0
Frankfurt A. M.
Country [31] 0 0
Germany
State/province [31] 0 0
Hannover
Country [32] 0 0
Germany
State/province [32] 0 0
Heidelberg
Country [33] 0 0
Germany
State/province [33] 0 0
Herne
Country [34] 0 0
Germany
State/province [34] 0 0
Jena
Country [35] 0 0
Germany
State/province [35] 0 0
Kiel
Country [36] 0 0
Germany
State/province [36] 0 0
Magdeburg
Country [37] 0 0
Germany
State/province [37] 0 0
Münster
Country [38] 0 0
Germany
State/province [38] 0 0
Neustadt
Country [39] 0 0
Germany
State/province [39] 0 0
Stade
Country [40] 0 0
Hungary
State/province [40] 0 0
Budapest N/A
Country [41] 0 0
Hungary
State/province [41] 0 0
Budapest
Country [42] 0 0
Hungary
State/province [42] 0 0
Békéscsaba
Country [43] 0 0
Hungary
State/province [43] 0 0
Mosonmagyarovar
Country [44] 0 0
Hungary
State/province [44] 0 0
Szekszárd
Country [45] 0 0
Israel
State/province [45] 0 0
Hadera
Country [46] 0 0
Israel
State/province [46] 0 0
Haifa
Country [47] 0 0
Israel
State/province [47] 0 0
Jerusalem
Country [48] 0 0
Israel
State/province [48] 0 0
Nazareth
Country [49] 0 0
Israel
State/province [49] 0 0
Ramat Gan
Country [50] 0 0
Israel
State/province [50] 0 0
Rechovot
Country [51] 0 0
Netherlands
State/province [51] 0 0
Amsterdam Zuidoost
Country [52] 0 0
Netherlands
State/province [52] 0 0
Amsterdam
Country [53] 0 0
Netherlands
State/province [53] 0 0
Maastricht
Country [54] 0 0
Netherlands
State/province [54] 0 0
Rotterdam
Country [55] 0 0
Poland
State/province [55] 0 0
Elblag
Country [56] 0 0
Poland
State/province [56] 0 0
Lodz
Country [57] 0 0
Poland
State/province [57] 0 0
Sopot
Country [58] 0 0
Poland
State/province [58] 0 0
Warszawa
Country [59] 0 0
Romania
State/province [59] 0 0
Bucharest
Country [60] 0 0
Romania
State/province [60] 0 0
Bucuresti
Country [61] 0 0
Romania
State/province [61] 0 0
Constanta
Country [62] 0 0
Romania
State/province [62] 0 0
Iasi
Country [63] 0 0
Romania
State/province [63] 0 0
Timisoara
Country [64] 0 0
Russian Federation
State/province [64] 0 0
Kazan N/A
Country [65] 0 0
Russian Federation
State/province [65] 0 0
Nizny Novgorod
Country [66] 0 0
Russian Federation
State/province [66] 0 0
Novosibirsk
Country [67] 0 0
Russian Federation
State/province [67] 0 0
Omsk
Country [68] 0 0
Russian Federation
State/province [68] 0 0
Rostov-On-Don
Country [69] 0 0
Russian Federation
State/province [69] 0 0
Ryazan
Country [70] 0 0
Russian Federation
State/province [70] 0 0
Saint Petersburg
Country [71] 0 0
Russian Federation
State/province [71] 0 0
St Petersburg
Country [72] 0 0
Russian Federation
State/province [72] 0 0
St-Petersburg
Country [73] 0 0
Russian Federation
State/province [73] 0 0
Stavropol
Country [74] 0 0
Russian Federation
State/province [74] 0 0
Ufa
Country [75] 0 0
Russian Federation
State/province [75] 0 0
Yaroslavl
Country [76] 0 0
Ukraine
State/province [76] 0 0
Donetsk
Country [77] 0 0
Ukraine
State/province [77] 0 0
Ivano-Frankovsk
Country [78] 0 0
Ukraine
State/province [78] 0 0
Kharkiv
Country [79] 0 0
Ukraine
State/province [79] 0 0
Kiev
Country [80] 0 0
Ukraine
State/province [80] 0 0
Kiiev
Country [81] 0 0
Ukraine
State/province [81] 0 0
Kyiv
Country [82] 0 0
Ukraine
State/province [82] 0 0
Lviv
Country [83] 0 0
Ukraine
State/province [83] 0 0
Odessa
Country [84] 0 0
Ukraine
State/province [84] 0 0
Ternopil
Country [85] 0 0
Ukraine
State/province [85] 0 0
Uzhgorod
Country [86] 0 0
Ukraine
State/province [86] 0 0
Vinnitsa
Country [87] 0 0
Ukraine
State/province [87] 0 0
Zaporizhzhia
Country [88] 0 0
Ukraine
State/province [88] 0 0
Zhaporozhia 69104

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Janssen Research & Development, LLC
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of the study is to evaluate dose response of JNJ-54781532 in participants with
moderately to severely active ulcerative colitis (UC).
Trial website
https://clinicaltrials.gov/ct2/show/NCT01959282
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Janssen Research & Development, LLC Clinical Trial
Address 0 0
Janssen Research & Development, LLC
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT01959282